Literature DB >> 12047755

The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis.

Javier Rangel Moreno1, Iris Estrada García, María De La Luz García Hernández, Diana Aguilar Leon, Ricardo Marquez, Rogelio Hernández Pando.   

Abstract

Prostaglandins (PG) are potent mediators of intercellular communication, and PGE2 at high concentration is immunosuppressive for T-cell-mediated immunity. We studied the kinetics of PGE2 production and the expression of the enzymes related to its synthesis during the course of experimental pulmonary tuberculosis. Secondly, we analysed the pathological and immunological changes produced by the pharmacological suppression of PG production. In BALB/c mice infected via the trachea with Mycobacterium tuberculosis H37Rv there is an initial phase of partial resistance, dominated by type 1 cytokines plus tumour necrosis factor-alpha (TNF-alpha) and expression of the inducible form of nitric oxide synthase (iNOS), followed by a phase of progressive disease. During the early phase of the infection some activated macrophages located in the alveolar-capillary interstitium and in granulomas showed strong PGE2 immunostaining. However, PGE2 concentrations were relatively low and stable. Animals in this early phase of infection were treated with niflumic acid, a potent and specific blocker of cyclo-oxygenase 2, the rate-limiting enzyme of PG production. In comparison with control animals, the suppression of PG synthesis produced higher inflammation and expression of TNF-alpha, interleukin-1alpha and interferon-gamma (IFN-gamma), but almost complete disappearance of iNOS expression, which coexisted with a significant increment of bacterial load. The late progressive phase in this experimental model is characterized by progressive pneumonia, small granulomas and diminished expression of IFN-gamma, TNF-alpha and iNOS in coexistence with high expression of IL-4. Strong PGE2 immunostaining was seen in foamy macrophages localized in the pneumonic areas, and the PGE2 concentration was four-fold higher in this late phase of infection than during the early phase. When PG production was suppressed in animals suffering advanced phase infection, a significant reduction of pneumonia and bacillus load with striking increment of granuloma size was seen, and the expression of IFN-gamma, TNF-alpha and iNOS was also improved. These findings demonstrate a significant participation of PGE2 in the pathogenesis of pulmonary tuberculosis, showing that during the early phase of the infection there are low PGE2 concentrations which contribute to iNOS expression permitting the temporal control of bacillus growth, while the high PGE2 concentrations during the late phase of the disease contribute to down-regulate cell-mediated immunity, permitting disease progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12047755      PMCID: PMC1782721          DOI: 10.1046/j.1365-2567.2002.01403.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

Review 1.  The pathogenesis of tuberculosis.

Authors:  G A Rook; R Hernandez-Pando
Journal:  Annu Rev Microbiol       Date:  1996       Impact factor: 15.500

2.  A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples.

Authors:  P Chomczynski
Journal:  Biotechniques       Date:  1993-09       Impact factor: 1.993

Review 3.  Lipid mediator networks in cell signaling: update and impact of cytokines.

Authors:  C N Serhan; J Z Haeggström; C C Leslie
Journal:  FASEB J       Date:  1996-08       Impact factor: 5.191

4.  Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines.

Authors:  M Betz; B S Fox
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

5.  Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation.

Authors:  A Ristimäki; S Garfinkel; J Wessendorf; T Maciag; T Hla
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

Review 6.  A new view of prostaglandin E regulation of the immune response.

Authors:  R P Phipps; S H Stein; R L Roper
Journal:  Immunol Today       Date:  1991-10

7.  Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes.

Authors:  S L Hempel; M M Monick; G W Hunninghake
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

8.  Prostaglandin E2 regulates inducible nitric oxide synthase in the murine macrophage cell line J774.

Authors:  S Milano; F Arcoleo; M Dieli; R D'Agostino; P D'Agostino; G De Nucci; E Cillari
Journal:  Prostaglandins       Date:  1995-02

9.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.

Authors:  F Fossiez; O Djossou; P Chomarat; L Flores-Romo; S Ait-Yahia; C Maat; J J Pin; P Garrone; E Garcia; S Saeland; D Blanchard; C Gaillard; B Das Mahapatra; E Rouvier; P Golstein; J Banchereau; S Lebecque
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

10.  Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.

Authors:  T C van der Pouw Kraan; L C Boeije; R J Smeenk; J Wijdenes; L A Aarden
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  57 in total

1.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Expression of cyclooxygenase-2, alpha 1-acid-glycoprotein and inducible nitric oxide synthase in the developing lesions of murine leprosy.

Authors:  Mayra Silva Miranda; Kendy Wek Rodríguez; Erasmo Martínez Cordero; Oscar Rojas-Espinosa
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

3.  Prostaglandin E2 Inhibits the Ability of Neutrophils to Kill Listeria monocytogenes.

Authors:  Michelle G Pitts; Sarah E F D'Orazio
Journal:  J Immunol       Date:  2019-05-06       Impact factor: 5.422

Review 4.  Prostaglandin E2 as a Regulator of Immunity to Pathogens.

Authors:  Giovanny J Martínez-Colón; Bethany B Moore
Journal:  Pharmacol Ther       Date:  2017-12-22       Impact factor: 12.310

5.  LL-37 immunomodulatory activity during Mycobacterium tuberculosis infection in macrophages.

Authors:  Flor Torres-Juarez; Albertina Cardenas-Vargas; Alejandra Montoya-Rosales; Irma González-Curiel; Mariana H Garcia-Hernandez; Jose A Enciso-Moreno; Robert E W Hancock; Bruno Rivas-Santiago
Journal:  Infect Immun       Date:  2015-09-08       Impact factor: 3.441

Review 6.  Macrophage immunoregulatory pathways in tuberculosis.

Authors:  Murugesan V S Rajaram; Bin Ni; Claire E Dodd; Larry S Schlesinger
Journal:  Semin Immunol       Date:  2014-10-30       Impact factor: 11.130

7.  Control of experimental pulmonary tuberculosis depends more on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins.

Authors:  C Peres-Buzalaf; L de Paula; F G Frantz; E M Soares; A I Medeiros; M Peters-Golden; C L Silva; L H Faccioli
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2011-05-31       Impact factor: 4.006

8.  An important role of prostanoid receptor EP2 in host resistance to Mycobacterium tuberculosis infection in mice.

Authors:  Vandana Kaul; Debapriya Bhattacharya; Yogesh Singh; Luc Van Kaer; Marc Peters-Golden; William R Bishai; Gobardhan Das
Journal:  J Infect Dis       Date:  2012-10-02       Impact factor: 5.226

9.  Incidence, etiopathogenesis and pathological aspects of genitourinary tuberculosis in India: A journey revisited.

Authors:  Prasenjit Das; Arvind Ahuja; Siddhartha Datta Gupta
Journal:  Indian J Urol       Date:  2008-07

10.  Persistent inactivation of macrophage cyclooxygenase-2 in mycobacterial pulmonary inflammation.

Authors:  Tsutomu Shinohara; Traci Pantuso; Shizuka Shinohara; Mari Kogiso; Quentin N Myrvik; Ruth Ann Henriksen; Yoshimi Shibata
Journal:  Am J Respir Cell Mol Biol       Date:  2008-12-18       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.